Promoter hypermethylation of multiple genes in hydatidiform mole and choriocarcinoma

被引:65
作者
Xue, WC
Chan, KYK
Feng, HC
Chiu, PM
Ngan, HYS
Tsao, SW
Cheung, ANY
机构
[1] Univ Hong Kong, Queen Mary Hosp, Hong Kong Jockey Club Clin Res Ctr, Dept Pathol, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Queen Mary Hosp, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China
[3] Univ Hong Kong, Queen Mary Hosp, Dept Anat, Hong Kong, Hong Kong, Peoples R China
关键词
D O I
10.1016/S1525-1578(10)60528-4
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The methylation status of genes in hydatidiform mole and choriocarcinoma and its significance is relatively unexplored. We investigated the methylation status of the promoter regions of six genes, p16, HIC-1, TIMP3, GSTP1, death-associated protein kinase (DAPK), and E-cadherin in 54 hydatidiform moles, five choriocarcinomas, and 10 first trimester placenta by methylation-specific polymerase chain reaction (PCR). Immunohistochemical expression of p16, TIMP3, and E-cadherin, and quantitative real-time RT-PCR of p16 was also performed. Among the six genes examined, the promoter region of four genes (E-cadherin, HIC-1, p16, TIMP3) in choriocarcinoma and three genes (E-cadherin, HIC-1, p16) in hydatidiform mole exhibited aberrant methylation whereas none was hypermethylated in normal placenta. There was a significant correlation between methylation and reduced expression of p16, E-cadherin, and TIMP3 (P < 0.001). Fifteen of the 54 patients with hydatidiform mole developed gestational trophoblastic neoplasia requiring chemotherapy. Promoter hypermethylation of p16 alone, or combined with E-cadherin, was significantly correlated to such development (P = 0.001, 0.0005, respectively). Hypermethylation of multiple genes, especially p16, might be related to the subsequent development of gestational trophoblastic neoplasia.
引用
收藏
页码:326 / 334
页数:9
相关论文
共 49 条
[1]  
Ahonen M, 1998, CANCER RES, V58, P2310
[2]   Association of IGF2 and H19 imprinting with choriocarcinoma development [J].
Arima, T ;
Matsuda, T ;
Takagi, N ;
Wake, N .
CANCER GENETICS AND CYTOGENETICS, 1997, 93 (01) :39-47
[3]  
Bass KE, 1997, DEV GENET, V21, P61, DOI 10.1002/(SICI)1520-6408(1997)21:1<61::AID-DVG7>3.3.CO
[4]  
2-B
[5]   Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3 [J].
Bian, JH ;
Wang, YL ;
Smith, MR ;
Kim, H ;
Jacobs, C ;
Jackman, J ;
Kung, HF ;
Colburn, NH ;
Sun, Y .
CARCINOGENESIS, 1996, 17 (09) :1805-1811
[6]   Promoter methylation analysis on micro-dissected paraffin-embedded tissues using bisulfite treatment and PCR-SSCP [J].
Bian, YS ;
Yan, P ;
Osterheld, MC ;
Fontolliet, C ;
Benhattar, J .
BIOTECHNIQUES, 2001, 30 (01) :66-+
[7]   Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway [J].
Bond, M ;
Murphy, G ;
Bennett, MR ;
Newby, AC ;
Baker, AH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (16) :13787-13795
[8]  
Chan KYK, 2002, CANCER RES, V62, P4151
[9]   Pathology of gestational trophoblastic diseases [J].
Cheung, ANY .
BEST PRACTICE & RESEARCH IN CLINICAL OBSTETRICS & GYNAECOLOGY, 2003, 17 (06) :849-868
[10]   Telomerase activity in gestational trophoblastic disease [J].
Cheung, ANY ;
Zhang, DK ;
Liu, Y ;
Ngan, HYS ;
Shen, DS ;
Tsao, SW .
JOURNAL OF CLINICAL PATHOLOGY, 1999, 52 (08) :588-592